# Treatment of Participants With Primary or Secondary Progressive Multiple Sclerosis

> **NCT07477639** · PHASE1,PHASE2 · RECRUITING · sponsor: **Tr1X, Inc.** · enrollment: 39 (estimated)

## Conditions studied

- Primary Progressive Multiple Sclerosis
- Secondary Progressive Multiple Sclerosis (SPMS)
- Multiple Sclerosis
- Multiple Sclerosis (MS) Primary Progressive
- Multiple Sclerosis (MS) Secondary Progressive

## Interventions

- **BIOLOGICAL:** TRX319
- **DRUG:** Bendamustine

## Key facts

- **NCT ID:** NCT07477639
- **Lead sponsor:** Tr1X, Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2026-03
- **Primary completion:** 2028-08
- **Final completion:** 2029-01
- **Target enrollment:** 39 (ESTIMATED)
- **Last updated:** 2026-03-19


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07477639

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07477639, "Treatment of Participants With Primary or Secondary Progressive Multiple Sclerosis". Retrieved via AI Analytics 2026-09-16 from https://api.ai-analytics.org/clinical/NCT07477639. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*